SCHEMBL114675

SCHEMBL114675

Cc1nc(-c2cnccc2Cl)c2ncn(C3CCCCO3)c2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 1/20 0.50
CYP2C19 P33261 1/20 0.43
FLT3 P36888 4/20 0.41
CYP1A2 P05177 2/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 2/20 0.39
TP53 P04637 1/20 0.39
CYP2C9 P11712 1/20 0.39
NFKB1 P19838 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
APEX1 P27695 1/20 0.39
PI4KA P42356 1/20 0.39
BLM P54132 1/20 0.39
ADCY1 Q08828 1/20 0.39
PI4K2B Q8TCG2 1/20 0.39
PI4K2A Q9BTU6 1/20 0.39
PI4KB Q9UBF8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31186403 0.82 YTHDC1 (0.47) YTHDC1CYP2C19FLT3CYP1A2TSHR
SCHEMBL115435 0.80 YTHDC1 (0.49) YTHDC1CYP2C19FLT3CYP1A2TSHR
SCHEMBL114895 0.79 YTHDC1 (0.46) YTHDC1CYP2C19FLT3CYP1A2TSHR
SCHEMBL29878036 0.79 YTHDC1 (0.46) YTHDC1CYP2C19FLT3CYP1A2TSHR
SCHEMBL112713 0.79 YTHDC1 (0.62) YTHDC1CYP2C19FLT3CYP1A2TSHR
SCHEMBL115200 0.78 YTHDC1 (0.48) YTHDC1CYP2C19FLT3CYP1A2TSHR
SCHEMBL13798746 0.77 YTHDC1 (0.59) YTHDC1CYP2C19FLT3CYP1A2TSHR
SCHEMBL115879 0.76 CYP2C19 (0.45) YTHDC1CYP2C19FLT3CYP1A2TSHR
SCHEMBL14296957 0.75 YTHDC1 (0.47) YTHDC1CYP2C19FLT3CYP1A2TSHR
SCHEMBL166953 0.74 YTHDC1 (0.43) YTHDC1CYP2C19FLT3CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424859-B1 INHIBITORS OF PI3 KINASE AND / OR MTOR AMGEN INC (US) 2015-04-08 EP disclosed
US-8772480-B2 Inhibitors of PI3 kinase and/or mTOR AMGEN INC. (US) 2014-07-08 US disclosed
US-20130079303-A1 Inhibitors of PI3 Kinase and/or mTOR AMGEN INC. (US) 2013-03-28 US disclosed
US-8362241-B2 Inhibitors of PI3 kinase and/or mTOR AMGEN INC. (US) 2013-01-29 US disclosed
EP-2424859-A1 INHIBITORS OF PI3 KINASE AND / OR MTOR Amgen, Inc (US) 2012-03-07 EP disclosed
WO-2010126895-A1 INHIBITORS OF PI3 KINASE AND / OR MTOR AMGEN INC. (US) 2010-11-04 WO disclosed
US-20100273764-A1 INHIBITORS OF PI3 KINASE AND/OR MTOR AMGEN INC. (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273764-A1 INHIBITORS OF PI3 KINASE AND/OR MTOR MTOR, PIK3CA, PIK3CD YTHDC1 4746/4885CYP2C19 1960/4885FLT3 923/4885
US-20130079303-A1 Inhibitors of PI3 Kinase and/or mTOR MTOR, PIK3CA, PIK3CD YTHDC1 4746/4885CYP2C19 1960/4885FLT3 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.